Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin plus chemotherapy vs chemotherapy plus placebo in FLT3-mutation negative AML
jRCT2080224610Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Midostaurin + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: Event-free survival (EFS). Started Mar 2019; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080224610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224610.